Alvotech (ALVO) Climbed, But What Is Behind The Latest Attention?

Alvotech (NasdaqGM:ALVO) shares are trading against the backdrop of a fresh product milestone, as the business and Advanz Pharma have filed a European application for AVT29, a proposed biosimilar to Eylea 8 mg.

Against that backdrop, Alvotech’s 90 day share price return of 53.47% points to building momentum, even though the 1 year total shareholder return is down 39.31%. The latest 2.71% one day move to US$5.31 comes after a 5.78% 30 day gain and recent manufacturing and partnership announcements.

Scan for other biosimilar specialists showing similar momentum and manufacturing progress by reviewing the 20 high quality undiscovered gems alongside Alvotech’s latest moves in retinal treatments and capacity expansion.

Alvotech now appears more like a scaled biosimilar platform than a single product story. After a 90 day surge and a longer term share price slide, does the current US$5.31 tag fairly reflect that reality?

Most Popular Narrative: 22% Undervalued

The most followed valuation narrative puts Alvotech’s fair value at $6.80, above the last close at $5.31. This frames the current rally as only a partial catch up to that estimate.

Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off patent, potentially driving a step-change in topline revenue once approvals are secured.

See why 14 investors see Alvotech as 22% undervalued.

Result: Fair Value of $6.80 (UNDERVALUED)

Still, heavy debt relative to a loss of US$179.6 million and reliance on unpredictable milestone payments could quickly challenge the view that the stock is 22% undervalued.

Find out about the key risks to this Alvotech narrative.

Next Steps

Mixed messages in the recent Alvotech share price and valuation narrative can feel messy, so move quickly, review the numbers, and weigh both the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Alvotech?

If you only stop at Alvotech, you risk missing other stocks that fit your style, your risk appetite, and the kind of portfolio balance you actually want.

• Target higher income potential by reviewing the 8 dividend fortresses that could support a portfolio focused on strong cash payouts.
• Prioritise capital preservation and steadier journeys by scanning the 32 resilient stocks with low risk scores that score well on resilience.
• Hunt for future leaders early by checking the 20 high quality undiscovered gems before broader attention arrives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com